ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Alliances and Collaborations Statement [Line Items]
Net sales	$ 5,454	$ 5,345	$ 5,434	$ 5,011	$ 5,111	$ 4,798	$ 4,768	$ 4,807	$ 21,244	$ 19,484	$ 18,808
Deferred income	1,203				1,297				1,203	1,297
ONGLYZA KOMBIGLYZE [Member]
Alliances and Collaborations Statement [Line Items]
Net sales									473	158	24
AstraZeneca [Member] | ONGLYZA KOMBIGLYZE [Member]
Alliances and Collaborations Statement [Line Items]
Net sales									473	158	24
Profit sharing expense									207	67	11
Commercialization expense reimbursements to/(from) AstraZeneca									(40)	(33)	(15)
AstraZeneca [Member] | ONGLYZA KOMBIGLYZE [Member] | Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Total upfront, milestone and other licensing payments	300								300
Upfront, milestone and other licensing payments received										50	150
Deferred income	230				254				230	254
Potential additional sales based milestone receipts	300								300
AstraZeneca [Member] | dapagliflozin [Member] | Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Total upfront, milestone and other licensing payments	170								170
Upfront, milestone and other licensing payments received									120
Deferred income	142				36				142	36
Potential additional development and regulatory milestone receipts	230								230
Potential additional sales based milestone receipts	390								390
AstraZeneca [Member] | ONGLYZA, KOMBIGLYZE and dapagliflozin [Member]
Alliances and Collaborations Statement [Line Items]
Research and development reimbursements to/(from) collaboration partner									40	19	(38)
AstraZeneca [Member] | ONGLYZA, KOMBIGLYZE and dapagliflozin [Member] | Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Amortization income - upfront, milestone and other licensing payments									$ (38)	$ (28)	$ (16)